PROCEPT BioRobotics Corp
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
PRCT$22.37+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements: Consolidated Balance Sheets F-
(in thousands, except per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $286,503 | $333,725 |
| Accounts receivable, net, | 83,533 | 83,496 |
| Inventory | 70,694 | 56,168 |
| Prepaid expenses and other current assets | 9,648 | 8,453 |
| Total current assets | 450,378 | 481,842 |
| Restricted cash, non-current | 3,038 | 3,038 |
| Property and equipment, net | 30,399 | 26,709 |
| Operating lease right-of-use assets, net | 17,538 | 18,941 |
| Intangible assets, net | 709 | 932 |
| Other assets | 6,019 | 2,555 |
| Total assets | $508,081 | $534,017 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $17,285 | $10,032 |
| Accrued compensation | 23,175 | 21,537 |
| Deferred revenue | 13,048 | 9,565 |
| Operating leases, current | 2,214 | 1,910 |
| Loan facility derivative liability | — | 2,000 |
| Other current liabilities | 10,073 | 8,089 |
| Total current liabilities | 65,795 | 53,133 |
| Long-term debt | 51,615 | 51,472 |
| Operating leases, non-current | 24,654 | 26,868 |
| Other non-current liabilities | 147 | 324 |
| Total liabilities | 142,211 | 131,797 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value; | ||
| Authorized shares: 10,000 at December 31, 2025 and 2024, respectively | ||
| Issued and outstanding shares: none at December 31, 2025 and 2024 | — | — |
| Common stock, $0.00001 par value; | ||
| Authorized shares: 300,000 at December 31, 2025 and 2024, respectively | ||
| Issued and outstanding shares: 56,323 and 54,718 at December 31, 2025 and 2024 | — | — |
| Additional paid-in capital | 1,007,390 | 948,091 |
| Accumulated other comprehensive gain | 37 | 114 |
| Accumulated deficit | (641,557) | (545,985) |
| Total stockholders’ equity | 365,870 | 402,220 |
| Total liabilities and stockholders’ equity | $508,081 | $534,017 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.